Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;24(4):712-723.
doi: 10.1007/s12094-022-02802-1. Epub 2022 Mar 26.

SEOM clinical guideline emesis (2021)

Margarita Majem  1 , Ramon de Las Peñas  2 , Juan Antonio Virizuela  3 , Luís Cabezón-Gutiérrez  4 , Patricia Cruz  5 , Rafael Lopez-Castro  6 , Miriam Méndez  7 , Rebeca Mondéjar  8 , María Del Mar Muñoz  9 , Yolanda Escobar  10
Affiliations

SEOM clinical guideline emesis (2021)

Margarita Majem et al. Clin Transl Oncol. 2022 Apr.

Erratum in

Abstract

Among the side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most feared given its high prevalence, affecting up to 40% of patients. It can impair patient's quality of life and provoke low adherence to cancer treatment or chemotherapy dose reductions that can comprise treatment efficacy. Suffering CINV depends on factors related to the intrinsic emetogenicity of antineoplastic drugs and on patient characteristics. CINV can appear at different times regarding the administration of antitumor treatment and the variability of risk according to the different antitumor regimens has, as a consequence, the need for a different and adapted antiemetic treatment prophylaxis to achieve the desired objective of complete protection of the patient in the acute phase, in the late phase and in the global phase of emesis. As a basis for the recommendations, the level of emetogenicity of anticancer treatment is considered and they are classified as high, moderate, low and minimal emetogenicity and these recommendations are based on the use of antiemetic drugs with a high therapeutic index: anti 5-HT, anti-NK and steroids. Despite having highly effective treatments, clinical reality shows that they are not applied enough, so evidence-based recommendations are needed to show the best options and help in decision-making. To cover all the antiemetic prophylaxis options, we have also included recommendations for oral treatments, multiday regimens and radiation-induced emesis prevention.

Keywords: Chemotherapy; Emesis; Nausea; Vomiting.

PubMed Disclaimer

Conflict of interest statement

MMT reports grants from Bristol Myers Squibb, Roche and AstraZeneca, personal fees from BMS; Astra Zeneca, Roche, MSD, Boehringer Ingelheim, Takeda, Sanofi-Aventis, Novartis, Vifor and Bayer outside the submitted work. LCG reports personal fees from Boehringer Ingelheim,Astra Zeneca, Roche and Bristol Myers Squibb, Merck Serono, Ipsen Pharma, Lilly, Amgen, Angelini, Grunenthal, Kyowa Kirin, Mundipharma, Pfizer, Rovi and Leo Pharma. MMG reports personal fees from Pfizer and Sanofi-Aventis. RDLP, JAV, PC, RLC, MM, RM, MMM, YE have nothing to disclose.

References

    1. Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260–1267. doi: 10.1093/annonc/mdx100. - DOI - PMC - PubMed
    1. Moretti EW, Robertson KM, El-Moalem H, Gan TJ. Intraoperative colloid administration reduces postoperative nausea and vomiting and improves postoperative outcomes compared with crystalloid administration. Anesth Analg. 2003;96(2):611–617. doi: 10.1213/00000539-200302000-00056. - DOI - PubMed
    1. Krikorian S, Pories S, Tataronis G, Caughey T, Chervinsky K, Lotz M, et al. Adherence to oral chemotherapy: challenges and opportunities. J Oncol Pharm Pract. 2019;25(7):1590–1598. doi: 10.1177/1078155218800384. - DOI - PubMed
    1. Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer. 2020;28(1):73–78. doi: 10.1007/s00520-019-04778-1. - DOI - PubMed
    1. de Las PR, Blasco A, De Castro J, Escobar Y, Garcia-Campelo R, Gurpide A, et al. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016) Clin Transl Oncol. 2016;18(12):1237–1242. doi: 10.1007/s12094-016-1583-0. - DOI - PMC - PubMed

MeSH terms